News & Events

19 September, 2019

BrainsWay Announces Further Leadership Transition to U.S.

Company Intends to Appoint U.S.-Based CEO

26 August, 2019

BrainsWay Reports Second Quarter 2019 Financial Results and Operational Highlights

Company also announces changes to U.S. Management Team

18 July, 2019

Groundbreaking Study Demonstrates Advantages of BrainsWay Deep TMS in Treating Major Depressive Disorder

First head-to-head, randomized controlled trial of its kind comparing Deep TMS, TMS and medication in...

27 June, 2019

New Data Published in American Journal of Psychiatry Further Substantiates BrainsWay’s Deep TMS System for the Treatment of Patients with Obsessive Compulsive Disorder

First non-invasive device for OCD achieves 45% response rate among patients after one month follow up,...

24 June, 2019

BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder

Since receiving De Novo clearance from FDA in August 2018, the Company has shipped OCD coils to 100 sites...

13 June, 2019

BrainsWay To Present At The 2019 Raymond James Life Sciences And MedTech Conference

JERUSALEM and HACKENSACK, N.J., June 13, 2019 – BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay”...

22 May, 2019

BrainsWay Announces its Multicenter Smoking Cessation Study Has Reached Target Enrollment

More than 260 participants have been enrolled to the study

5 March, 2019

BrainsWay Announces New Clinical Support Program for Physicians Treating Obsessive-Compulsive Disorder: – “BrainsWay OCD Launchpad to Success”

Program supports physicians in successfully implementing OCD Deep TMS treatment, through in-depth clinical...

4 March, 2019

BrainsWay Expands Intellectual Property Position by Obtaining Rights to Multi-Channel Transcranial Magnetic Stimulation Patent Portfolio

Acquires Multi-Channel TMS Patent Portfolio from TMS Innovations. Enters into an Exclusive Option Agreement...

20 February, 2019

BrainsWay Expands its Deep TMS Commercial Footprint into Asia Pacific

Enters into an Agreement to Distribute its Deep Transcranial Magnetic Stimulation System in South Korea.

29 January, 2019

BrainsWay Receives PMDA Approval in Japan of Deep Transcranial Magnetic Stimulation System for Treatment of Major Depressive Disorder

Approval allows BrainsWay’s Deep TMS System to be marketed throughout Japan.

17 October, 2018

BrainsWay to Showcase Deep Transcranial Magnetic Stimulation System for the Treatment of Obsessive-Compulsive Disorder at the 2018 Annual Psych Congress

Showcase represents the public debut of BrainsWay’s Deep TMS system for OCD Healthcare providers will...

7 June, 2018

BrainsWay and Cohen Veterans Bioscience Announce Biomarker Research Collaboration in Post Traumatic Stress Disorder

Unique Biomarkers Sought to Enable Personalized Medicine Approach for Treatment of Post Traumatic Stress...

17 April, 2019

BrainsWay Ltd. Announces Pricing of Initial Public Offering of 2.5 Million American Depositary Shares

JERUSALEM, Israel, April 16, 2019 – BrainsWay Ltd. (NASDAQ: BWAY and TASE:BRIN) (“BrainsWay”)...

26 March, 2019

BrainsWay Reports Financial Results for Fourth Quarter and Full-Year 2018

Full-Year 2018 revenues of $16.4 million increased 47% over full-year 2017 Fourth quarter revenues of...